Those data focus on the mediation of antitumor activity by panobinostat's ability to induce HIF-1α protein degradation in endothelial cells, thus inhibiting tumor angiogenesis and potentiating anti-tumor activity. This evidence concerns the gene HIF1A and neoplasm.